The effects of augmenting clozapine with oxytocin in schizophrenia: An initial case series.

Marotta RF, Buono FD, Garakani A, Collins E, Cerrito B, David Rowe DR

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists1 May 2020Cited by 5 (Europe PMC)

PMID32343282DOI10.1177/104012372003200211PepBankPUB-32343282

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanCase report or seriesEfficacy outcome
In young adults with treatment-resistant schizophrenia on clozapine, adding sublingual oxytocin appeared to reduce negative symptoms.
In plain wordsIn 5 young adults with treatment-resistant schizophrenia, adding oxytocin to clozapine appeared to reduce negative symptoms. There was no control group.
Peptide
Oxytocin
Outcome
DecreaseNegative symptoms of schizophrenia
Study
n = 5
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
10 IU once daily to 20 IU three times daily · sublingualAs given in this study (human).
Source sentences
Summary
The augmentation of clozapine with sublingual OT in young adults with treatment-resistant schizophrenia appeared to reduce negative symptoms, maintain lowered positive symptoms, and increase occupational and social functioning (eg, return to work or school), as noted by family members.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective chart review evaluated outcomes for 5 young adult inpatients with treatment-resistant schizophrenia who were prescribed off-label oxytocin (OT; 10 IU/sublingual, 1 time per day, to 20 IU/sublingual, 3 times per day) after their therapeutic response to clozapine plateaued (dose range: 200 to 600 mg).
Report a problemFND-3234328201
02HumanCase report or seriesEfficacy outcome
In young adults with treatment-resistant schizophrenia on clozapine, adding sublingual oxytocin appeared to maintain lowered positive symptoms.
In plain wordsIn 5 young adults with treatment-resistant schizophrenia, positive symptoms stayed low after oxytocin was added to clozapine. There was no control group.
Peptide
Oxytocin
Outcome
No significant changePositive symptoms of schizophrenia
Study
n = 5
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
10 IU once daily to 20 IU three times daily · sublingualAs given in this study (human).
Source sentences
Summary
The augmentation of clozapine with sublingual OT in young adults with treatment-resistant schizophrenia appeared to reduce negative symptoms, maintain lowered positive symptoms, and increase occupational and social functioning (eg, return to work or school), as noted by family members.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective chart review evaluated outcomes for 5 young adult inpatients with treatment-resistant schizophrenia who were prescribed off-label oxytocin (OT; 10 IU/sublingual, 1 time per day, to 20 IU/sublingual, 3 times per day) after their therapeutic response to clozapine plateaued (dose range: 200 to 600 mg).
Report a problemFND-3234328202
03HumanCase report or seriesEfficacy outcome
In young adults with treatment-resistant schizophrenia on clozapine, adding sublingual oxytocin appeared to increase occupational and social functioning, as noted by family members.
In plain wordsIn 5 young adults with treatment-resistant schizophrenia, family members noted better work or school and social functioning after oxytocin was added to clozapine.
Peptide
Oxytocin
Outcome
IncreaseOccupational and social functioning
Study
n = 5
Outcome group
Quality of life · Mental health and mood
Studied dose
10 IU once daily to 20 IU three times daily · sublingualAs given in this study (human).
Source sentences
Summary
The augmentation of clozapine with sublingual OT in young adults with treatment-resistant schizophrenia appeared to reduce negative symptoms, maintain lowered positive symptoms, and increase occupational and social functioning (eg, return to work or school), as noted by family members.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective chart review evaluated outcomes for 5 young adult inpatients with treatment-resistant schizophrenia who were prescribed off-label oxytocin (OT; 10 IU/sublingual, 1 time per day, to 20 IU/sublingual, 3 times per day) after their therapeutic response to clozapine plateaued (dose range: 200 to 600 mg).
Report a problemFND-3234328203
04HumanCase report or seriesSafety outcome
In 5 young adults with treatment-resistant schizophrenia, the oxytocin augmentation of clozapine was well tolerated and continued for at least 1 year after discharge.
In plain wordsIn 5 young adults with treatment-resistant schizophrenia, adding oxytocin to clozapine was well tolerated for at least 1 year. There was no control group.
Peptide
Oxytocin
Outcome
No significant changeTolerability of oxytocin augmentation
Study
n = 5
Outcome group
Adverse events · Mental health and mood
Studied dose
10 IU once daily to 20 IU three times daily · sublingual · at least 1 yearAs given in this study (human).
Source sentences
Summary
The augmented treatment was well tolerated and continued for at least 1 year after discharge from the hospital, with continued outpatient follow-up by the treating psychiatrist.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective chart review evaluated outcomes for 5 young adult inpatients with treatment-resistant schizophrenia who were prescribed off-label oxytocin (OT; 10 IU/sublingual, 1 time per day, to 20 IU/sublingual, 3 times per day) after their therapeutic response to clozapine plateaued (dose range: 200 to 600 mg).
Report a problemFND-3234328204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 02:49 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.